Fecha de publicación: -- Fuente: WIPO "tomato" This disclosure describes a method for altering the proteome of a diseased heart, organ or tissue by contacting it with extracellular matrix (ECM) particles derived from decellularized 3D microtissues. In an example, the process involves restoring the normal ratio of collagen levels, modulating immune responses, improving mitochondrial function, and/or mitigating the effects of TGF-Beta, a growth factor associated with fibrosis. The ECM particles can be produced from human mesenchymal stem cells and retain bioactive components and structural properties of native tissue. Additionally, the disclosure outlines a composition for treating a diseased organ using these ECM particles, which are treated to enhance crosslinking, stability, injectability, and compatibility with patients.